The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease

Hepato-Gastroenterology

Volumn 52, Issue 66, 2005, Pages 1832-1835

  Yang, Moon Hee ^a   Son, Hee Jung ^a   Sung, Ji Dong ^a   Choi, Yoon Ho ^a   Koh, Kwang Cheol ^a,b   Yoo, Byung Chul ^a   Paik, Seung Woon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Apolipoprotein E; Fatty liver; Lipoprotein (a)

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FATTY LIVER; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGE DISTRIBUTION; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; LIPOPROTEIN(A); LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 28544434025     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hagberg JM, Wilund KR, Ferrell RE: APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics 2000; 4:101-108.
2. Hofker MH, van Vlijmen BJ, Havekes LM: Transgenic mouse models to study the role of apoE in hyperlipidemia and atherosclerosis. Atherosclerosis 1998; 137:1-11.
3. Plump AS, Breslow JL: Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr 1995; 15:495-518.
4. Kuipers F, Jong MC, Lin Y, et al: Impaired secretion of Very Low Density Lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest 1997; 100:2915-2922.
5. Mensenkamp AR, van Luyn MJA, van Goor H, et al: hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. J Hepatol 2000; 33:189-198.
6. Yoon KS, Beak SH, Shin ES, et al: Factors related to patients with fatty liver. J Korean Acad Fam Med 1997; 18:1426-1435.
7. Bartens W, Rader DJ, Talley G, et al: Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. Atherosclerosis 1994; 108:149-157.
8. Werba JP, Safa O, Gianfranceschi G, et al: Plasma triglycerides and lipoprotein(a): invere relationship in a hyperlipidemic Italian population. Atherosclerosis 1993; 101:203-211.
9. Sullivan DR, Lam CW, Jessup W, et al: Postprandial changes in apolipoprotein(a) concentration of triglyceride-rich lipoproteins can be reproduced by in vitro incubation: implications for underlying mechanism. Atherosclerosis 1993; 103:139-147.
10. Chun SI, Min WK, Kim JW, et al: Apolipoprotein E polymorphism and serum lipoprotein(a) concentrations in a Korean male population. Ann Clin Biochem 2001; 38:129-134.
11. Mehmet K, Cemil S, Ömer Y, et al: Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003; 37(2):177-182.
12. Alba LM, Lindor K: Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003; 17:977-986.
13. Hur KC, Chung WJ, Hwang JS, et al: Usefulness of ultrasonography in diagnosis of fatty liver. Korean J Gastroenterol 1998; 31:674-672.
14. Mulhall BP, Ong JP, Younossi ZM: Non-alcoholic fatty liver disease: An overview. J Gastroenterol and Hepatol 2002; 17:1136-1143.
15. Sheth SG, Gordon FD, Chopra S: Non-alcoholic steatohepatitis. Ann Intern Med 1997; 126:137-145.
16. Bugianesi E, Leone N, Vanni E, et al: Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134-140.
17. Powell EE, Cookey WG, Hanson R, et al: The natural history of nonalcoholic steatohepaitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74-80.
18. Lee RG: Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594-598.
19. Bacon BR, Farahvash MJ, Janney CG, et al: Nonalcoholic steatohepatitis: an espanded clinical entity. Gastroenterology 1994; 107:1103-1109.
20. Pinto HC, Baptista A, Camilo ME, et al: Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41:172-179.
21. Davignon J, Bouthillier D, Kogan S, et al: Apolipoprotein E polymorphism and athrosclerosis. Arteriosclerosis 1988; 8:1-21.
22. De Knijff P, Hevekes LM: Apolipoprotein E as a risk factor for coronary heart disease: A genetic and molecular biology approach. Curr Opin Lipidol 1996; 7:59-63.
23. Roll SC, Marley RW: The role of apolipoprotein E genetic variants in lipoprotein disorders. Intern Med 1992; 231:653-659.
24. Utermann G: Apolipoprotein E polymorphism in health and disease. Am Heart J 1987; 113:433-440.
25. Poirier J, Davignon J, Bouthillier D, et al: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342:697-699.
26. Kuusisto J, Koivisto K, Kervinen K, et al: Association of apoliprotein E phenotypes with late-onset Alzheimer's disease: population-based study. BMJ 1994; 309:636-638.
27. Lee DM, Lee SO, Mun BS, et al: Relation of apolipoprotein E polymorphism to clinically diagnosed fatty liver disease. Korean J Hepatol 2002; 8:355-362.
28. Utermann G, Hees M, Steinmetz A: Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 1977; 269:604-604.
29. Kesäniemi YA, Ehnholm C, Miettinen TA: Intestinal cholesterol absorption efficiency in man is related to apolipoprotein E phenotype. J Clin Invest 1987; 80:578-581.
30. Boerwinkle E, Leffert CC, Lin J, et al: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90:52-60.
31. Scanu AM, Fless GM: Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990; 85:1709-1715.
32. Berg K: Lp(a) lipoprotein: an overview. Chem Phys Lipids 1994; 67:9-16.